Nestlé Health Science, Geocann expand distribution of VESIsorb CBD delivery into Europe under Pure Encapsulation brand

Geocann (Fort Collins, CO) and Nestlé Health Science (Switzerland) launched broad-spectrum CBD soft-gel formulations with VESIsorb drug delivery system for improved absorption and bioavailability in the European market.

“We are extremely proud to expand our relationship with Nestlé’s healthcare professional brands into Europe after their success in the U.S. market this past year,” said Jesse Lopez, CEO and founder of Geocann, in a press release. “Their leadership team’s validation of science-backed and clinically-proven hemp products is an important milestone for our industry and provides exceptional credibility to the therapeutic benefits of cannabinoids formulated with VESIsorb.”

The first large-scale production was completed and delivered in early September, using only European resources—from the cultivation and extraction of the hemp biomass in Slovenia to the drug-delivery technology and soft-gel capsule production in Switzerland.

VESIsorb—a naturally self-assembling colloidal droplet delivery system that improves the bioavailability of poorly absorbed natural ingredients, such as cannabinoids and terpenes—is supported by pilot and peer-reviewed published studies. The peer-reviewed journal, Molecules, published the results of a double-blind, cross-over design study comparing the pharmacokinetic parameters of a broad-spectrum hemp extract formulated with VESIsorb to that of the same broad-spectrum hemp extract combined with medium chain triglyceride (MCT) oil. Overall, the VESIsorb formulation showed statistically significant improvements for all measured pharmacokinetic parameters.

“Together with Geocann, we share a passion and commitment to product safety, purity, and performance,” said Barry Ritz, PhD, chief science officer at Pure Encapsulations, in a press release. “Our partnership is built on a relentless effort to ensure these are the most science-backed CBD products in the world, setting the benchmark for what consumers expect and healthcare professionals demand.”

According to Lopez, in addition to recent pharmacokinetic studies and the stability data for its products, further investments in new clinical research focused on both pharmacokinetic performance and clinical end points are well under way. Additionally, multiple toxicology studies have been completed and will be published this year as part of the company’s FDA GRAS Notification and Novel Food application.